Table

Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021

Claire von Mollendorf

, Munkhchuluun Ulziibayar, Cattram D. Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, John de Campo, Margaret de Campo, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Eileen M. Dunne, Catherine Satzke, Tuya Mungun, and E. Kim Mulholland

Author affiliations: Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (C. von Mollendorf, C.D. Nguyen, J. de Campo, M. de Campo, E.M. Dunne, C. Satzke, E.K. Mulholland); The University of Melbourne, Melbourne (C. von Mollendorf, C.D. Nguyen, J. de Campo, M. de Campo, E.M. Dunne, C. Satzke, E.K. Mulholland); National Center for Communicable Diseases, Ulaanbaatar, Mongolia (M. Ulziibayar, P. Batsaikhan, B. Suuri, D. Luvsantseren, B. Tsolmon, T. Mungun); Ministry of Health, Ulaanbaatar (D. Narangerel); Mongolian National University of Medical Sciences, Ulaanbaatar (B. Tsolmon); World Health Organization, Ulaanbaatar (S. Demberelsuren); Peter Doherty Institute for Infection and Immunity, Melbourne (C. Satzke); London School of Hygiene and Tropical Medicine, London, UK (E.K. Mulholland)

Main Article

Carriage prevalence and prevalence ratios for pneumococcal carriage among 6,545 children with pneumonia before and after PCV13 availability, 4 districts, Mongolia, 2015–2021*

Pneumococcal type	Pre-PCV13, no./total	Pre-PCV13 prevalence, % (95% CI)	Post-PCV13 no./total	Post-PCV13 prevalence, % (95% CI)	Unadjusted prevalence ratio (95% CI)	Adjusted prevalence ratio (95% CI)†
Overall pneumococci
All districts	882/1,837	48.0 (45.7–50.3)	2,174/4,708	46.2 (44.7–47.6)	0.96 (0.91–1.02)	0.98 (0.92–1.04)
Bayanzurkh	263/657	40.0 (36.2–43.9)	363/905	40.1 (36.9–43.4)	1.00 (0.89–1.13)	1.06 (0.93–1.21)
Chingeltei	341/592	57.6 (53.5–61.6)	565/1,194	47.3 (44.4–50.2)	0.82 (0.75–0.90)	0.81 (0.73–0.90)
Songinokhairkhan	184/368	50.0 (44.8–55.2)	953/1,891	50.4 (48.1–52.7)	1.01 (0.90–1.13)	1.00 (0.89–1.12)
Sukhbaatar	94/220	42.7 (36.1–49.5)	293/718	40.8 (37.2–44.5)	0.95 (0.80–1.14)	0.95 (0.79–1.14)
PCV13 serotypes
All districts	548/1,742	31.4 (29.3–33.7)	742/4,304	17.2 (16.1–18.4)	0.55 (0.50–0.60)	0.56 (0.51–0.62)
Bayanzurkh	161/614	26.2 (22.8–29.9)	119/830	14.3 (12.0–16.9)	0.55 (0.44–0.68)	0.59 (0.47–0.75)
Chingeltei	200/566	35.3 (31.4–39.4)	205/1,077	19.0 (16.7–21.5)	0.54 (0.46–0.64)	0.53 (0.44–0.63)
Songinokhairkhan	127/354	35.9 (30.9–41.1)	306/1,737	17.6 (15.8–19.5)	0.49 (0.41–0.58)	0.50 (0.42–0.61)
Sukhbaatar	60/208	28.8 (22.8–35.5)	112/660	17.0 (14.2–20.0)	0.59 (0.45–0.77)	0.59 (0.44–0.78)
Non-PCV13 serotypes
All districts	329/1,742	18.9 (17.1–20.8)	1,170/4,304	27.2 (25.8–28.5)	1.44 (1.29–1.60)	1.49 (1.32–1.67)
Bayanzurkh	76/614	12.4 (9.9–15.2)	193/830	23.2 (20.4–26.3)	1.88 (1.47–2.40)	1.95 (1.49–2.55)
Chingeltei	152/566	26.8 (23.2–30.7)	286/1,077	26.5 (23.9–29.3)	0.99 (0.83–1.17)	0.96 (0.79–1.17)
Songinokhairkhan	69/354	19.5 (15.5–24.0)	550/1,737	31.7 (29.5–33.9)	1.62 (1.30–2.03)	1.57 (1.24–1.99)
Sukhbaatar	32/208	15.4 (10.8–21.0)	141/660	21.4 (18.3–24.7)	1.39 (0.98–1.97)	1.26 (0.88–1.81)

*Overall, PCV13 serotypes and non-PCV13 serotypes. PCV13, 13-valent pneumococcal conjugate vaccine. †Adjusted by using a common set of confounders: age, informal housing, other children <5 y of age in the home, coal used for fuel, household income, crowding, maternal education, season, and antimicrobial drug receipt 48 h before admission.

Main Article

Page created: January 31, 2024

Page updated: February 22, 2024

Page reviewed: February 22, 2024

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.